Cognitive Assessment for Stroke Patients: Reproductibility and Validity Study

Stroke Clinical Trial

— Casper  

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01904799
• Other study ID #: Benaim PHRC N 2012
• Status: Completed
• Phase: N/A
• Start date: January 2, 2015
• Est. completion date: March 29, 2019

Study information

• Verified date: July 2019
• Source: Centre Hospitalier Universitaire Dijon
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

After a CVA, all of the cognitive functions can be affected and analysed, but the presence of a language disorder may considerably hamper the evaluation of other functions.

The battery of rapid tests to screen for and quantify cognitive disorders, including the MMSE, the MOCA, the R-CAMCOG or the RBANS, are not suitable for aphasic patients because they contain items with a strictly verbal response. Because of this, inexperienced doctors cannot evaluate higher functions (other than language) of aphasics in routine practice. For the same reason, aphasics are regularly excluded from post-cva therapeutic protocols, whether or not the trial bears on the evolution of cognitive functions.

Nonetheless, it is possible to evaluate, at least roughly, all of the cognitive functions without resorting to language.

The investigator have developed , from validated tests and classical clinical manoeuvers, the Cognitive Assessment for Stroke Patients (CASP) :

• for the rapid screening (less than 15 minutes) and quantification of post-cva cognitive disorders (6 functions: language, apraxia, short-term memory, temporal orientation, impaired spatial/visio-construction and executive functions);

• the CASP can be used in most patients, including those with severe disorders of expression and moderate problems with comprehension, The format of these tests has been adapted so that severe disorders of expression (essentially left-hemisphere CVA), and left spatial impairment (right-hemisphere CVA) do not affect the ability to take the test. Its validity in terms of appearance and content were verified in 2011.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 263
• Est. completion date: March 29, 2019
• Est. primary completion date: March 29, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

For CVA patients

• patients hospitalised in rehabilitation after a first recent hemispheric CVA (less than 6 weeks) ;

• aged > 18;

• absence of severe disorders of oral comprehension (BDAE aphasia severity score >2 for comprehension);

• whatever the severity of oral expression disorders;

• who have been given clear written and oral information, and after the doctor has verified their ability to understand the protocol.

For " Control " patients (to evaluate divergent validity)

• patients hospitalised in rehabilitation units or geriatrics taking part in this study;

• aged > 18.

Exclusion Criteria:

For CVA patients

• patients who do not speak French;

• cognitive disorders known before the CVA;

• psychotic disorders known before the CVA;

• major visual disorders incompatible with reading, known before the CVA.

For " Control " patients (to evaluate divergent validity)

• patients who do not speak French;

• cognitive disorders known before the CVA;

• psychotic disorders known before the CVA;

• major visual disorders incompatible with reading, known before the CVA.

Related Conditions & MeSH terms

• Stroke

Intervention

Other:
• Cognitive Assessment test

Locations

Country	Name	City	State
France	CHU de Dijon	Dijon

Sponsors (1)

Lead Sponsor	Collaborator
Centre Hospitalier Universitaire Dijon

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	comprehensive assessment battery of higher functions		baseline
Primary	comprehensive assessment battery of higher functions		Evaluation at 3 ±1 days
Primary	comprehensive assessment battery of higher functions		Evaluation at 6 ± 2 weeks
Primary	test of visual memory		baseline
Primary	test of visual memory		Evaluation at 3 ±1 days
Primary	test of visual memory		Evaluation at 6 ± 2 weeks